课题基金 / 基金详情

Tolerogenic dual microparticle system for treatment of multiple sclerosis

Tolerogenic dual microparticle system for treatment of multiple sclerosis
用于治疗多发性硬化症的致耐受性双微粒系统
批准号:
9918870
负责人:
Dorina Avram
金额:
$52.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-05 至 2022-04-30

项目摘要

项目成果

Dorina Avram的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Multiple sclerosis (MS) is a debilitating, immune-mediated neurological disease that typically affects young adults, with higher frequency in women. In this disease immune cells target and destroy myelin in the central nervous system (CNS) causing demyelination and thus neurological alterations. There is no known cure for MS and many of the current treatments are not specific and suppress the function of the entire immune system. There is a great interest in development of novel, more specific and more effective therapies for MS. We developed a new therapy, which shows high efficiency in the treatment of Experimental Autoimmune Encephalomyelitis (EAE), the mouse model for MS, in a semitherapeutic setup. The treatment is based on delivery of specific myelin antigens and tolerogenic factors encapsulated in the FDA-approved poly(lactic-co- glycolic acid) (PLGA) microparticles (MPs) for controlled intracellular delivery through phagocytosable MPs, as well as for controlled delivery to surface receptors through non-phagocytosable MPs, thus constituting a dual MP system (dMP). The treatment is specific, being dependent on the specific myelin antigens, as MPs loaded with an irrelevant peptide did not block the disease. In addition, EAE blocking was dependent on encapsulation of the treating drugs, as soluble factors and empty particles were not effective in the treatment. We hypothesize that the therapeutic success translated in blocking of EAE by the dMP treatment is a consequence of tolerance induction. We thus propose to establish the mechanisms by which the dMP treatment blocks EAE. Additionally, we propose to test the dMP treatment in advanced stages of EAE, as well as in a remission/relapsing model and further optimize the regimen of treatment. The proposed studies in this application are of the highest significance, given its specificity and the fact that the therapeutic options for MS are limited and many of them lack the needed specificity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis
  • 批准号:
    10667165
  • 项目类别:
  • 资助金额:
    $79.83万
  • 财政年份:
    2023
  • 负责人:
    Dorina Avram
  • 依托单位:
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
  • 批准号:
    10391539
  • 项目类别:
  • 资助金额:
    $78.72万
  • 财政年份:
    2021
  • 负责人:
    Dorina Avram
  • 依托单位:
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
  • 批准号:
    10597043
  • 项目类别:
  • 资助金额:
    $78.72万
  • 财政年份:
    2021
  • 负责人:
    Dorina Avram
  • 依托单位:
Transcriptional control in innate lymphoid type II cells
  • 批准号:
    8732115
  • 项目类别:
  • 资助金额:
    $23.7万
  • 财政年份:
    2014
  • 负责人:
    Dorina Avram
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究